BioSpace News Archive

Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its participation in the KCSA Virtual Investor Conference on April 20th at 1:30pm ET..

TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing. Dempsey, who has more than two decades of experience in the ophthalmic pharmaceutical industry, is expected to accelerate TearClear’s business and commercial stra

Research Study to Utilize IVIG as Coronavirus Treatment for Adults Experiencing Respiratory Failure Following Use in Patients in San Diego and China

Tabula Rasa HealthCare®, Inc., a healthcare technology company advancing the field of medication safety, announced an expanded laboratory services agreement with CQuentia, a comprehensive analytics platform and molecular laboratory for personalized medicine.

Research advance enables study of neural circuit mechanisms underlying complex and clinically relevant behaviors, including dysfunction in neurological disease

MGTA-117 conditioning ADC-based program on track for initial clinical data in 2021 MGTA-145 stem cell mobilization Phase 1 program met all safety and efficacy endpoints and enrollment is complete in renal pharmacokinetic study; potential for initial Phase 2 data in 2020 CD45-ADC progressing in IND-enabling studies MGTA-456 Phase 2 trial in inherited metabolic disorders experiencing enrollment delay due to impact of novel coronavirus (COV

Patient-Centric Rare Disease Platform Expands to 12 Rare Diseases; Financing to Enable Launch of 20 New Conditions Within a Year

Lantheus Holdings to Host First Quarter 2020 Earnings Conference Call on April 30, 2020 at 8:00 a.m. Eastern Time

Quanta, Inc. (OTCPK: QNTA), an applied sciences company based on a quantum biology platform that significantly boosts the potency and efficiency of any plant-based matter, today announced that Eddy Pham, will join their board of advisors to help drive partnerships and product distribution for Quanta.